Minerva Surgical, Inc. (NASDAQ:UTRS) Short Interest Down 49.8% in August

Minerva Surgical, Inc. (NASDAQ:UTRS) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 72,600 shares, a drop of 49.8% from the August 15th total of 144,500 shares. Based on an average daily volume of 451,900 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Minerva Surgical

A number of large investors have recently added to or reduced their stakes in UTRS. Vanguard Group Inc. lifted its stake in shares of Minerva Surgical by 64.8% in the first quarter. Vanguard Group Inc. now owns 378,781 shares of the company’s stock worth $1,705,000 after buying an additional 148,915 shares during the last quarter. State Street Corp acquired a new position in Minerva Surgical during the 2nd quarter worth $36,000. AWM Investment Company Inc. boosted its holdings in Minerva Surgical by 20.2% during the fourth quarter. AWM Investment Company Inc. now owns 1,668,572 shares of the company’s stock valued at $373,000 after acquiring an additional 280,057 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Minerva Surgical by 284.7% during the second quarter. Geode Capital Management LLC now owns 128,749 shares of the company’s stock valued at $33,000 after acquiring an additional 95,284 shares during the period. Institutional investors own 89.55% of the company’s stock.

Minerva Surgical Trading Up 3.8 %

Shares of NASDAQ:UTRS opened at $0.20 on Thursday. The company has a current ratio of 2.55, a quick ratio of 1.56 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $35.76 million, a PE ratio of -0.25 and a beta of 1.35. Minerva Surgical has a 1 year low of $0.15 and a 1 year high of $1.42. The firm has a fifty day moving average price of $0.23 and a 200 day moving average price of $0.24.

Minerva Surgical (NASDAQ:UTRS) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The company had revenue of $13.39 million during the quarter, compared to analysts’ expectations of $13.92 million. Minerva Surgical had a negative return on equity of 151.34% and a negative net margin of 71.87%. Analysts expect that Minerva Surgical will post -0.22 EPS for the current fiscal year.

Minerva Surgical Company Profile

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.